Asahi Intecc USA, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.3Mgeneral payments (2019-2025)

$25Kresearch payments (2019-2025)

2,027clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $155K

2020 $128K

2021 $240K

2022 $120K

2023 $151K

2024 $218K

2025 $243K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Interventional Cardiology $688K

Cardiovascular Disease $179K

Vascular & Interventional Radiology $159K

Vascular Surgery $92K

Vascular Neurology $41K

Diagnostic Radiology $34K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

Clinician	Location	Specialty	General payments (2019-2025)
William Lombardi	Seattle, WA	Interventional Cardiology	$149,631.75
Mahmood Razavi	Orange, CA	Vascular & Interventional Radiology	$40,427.84
Ameer Hassan	Harlingen, TX	Vascular Neurology	$39,565.82
James Grantham	Kansas City, MO	Interventional Cardiology	$35,235.53
Jihad Mustapha	Grand Rapids, MI	Cardiovascular Disease	$33,043.95
Craig Walker	Houma, LA	Interventional Cardiology	$31,690.67
Tony De Martini	Springfield, IL	Interventional Cardiology	$29,166.95
Arun Kalyanasundaram	Marshfield, WI	Interventional Cardiology	$26,910.23
Rhian Davies	York, PA	Cardiovascular Disease	$24,420.77
Sreekumar Madassery	Chicago, IL	Vascular & Interventional Radiology	$20,465.13

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.